High Lp(a): A Systemic Vascular Threat Beyond the Heart
Irma Bagdoniene, Cardiologist Specializing in Prevention and Lipidology, Member of EAS, ESC and EAPC, shared on LinkedIn:
“Lp(a)’s threat goes far beyond the heart.
We often think of it mainly as a risk factor for heart attacks and strokes, but its impact actually involves the entire vascular system.
New data confirm that high Lp(a) is a causal risk factor for peripheral arterial disease, major adverse limb events, and abdominal aortic aneurysms. This risk stands independently of low-grade inflammation (hsCRP). Elevated Lp(a) by itself can drive these complications.
Key insights from the Copenhagen General Population Study and UK Biobank:
- Individuals in the top 1% of Lp(a) levels face nearly a threefold increased risk of PAD and major adverse limb events.
- Mendelian randomization studies support a causal relationship between genetically high Lp(a) and abdominal aortic aneurysms, with about a 40% increased risk per 50 mg/dL rise.
- This elevated risk persists regardless of hsCRP levels. Low inflammation does not eliminate the vascular harm from Lp(a).
- Four potent Lp(a)-lowering agents are currently in phase 3 trials (results expected between 2026 and 2029), holding promise to reshape prevention strategies across vascular diseases.
The clinical takeaway is straightforward.
We need to expand Lp(a) screening.”
Title: Lipoprotein(a) in cardiovascular disease with focus on peripheral arterial disease, major adverse limb events, abdominal aortic aneurysms and interaction with low-grade inflammation
Authors: Peter E. Thomas et al.
Read the full article.
Stay with Hemostasis Today to explore more from Irma Bagdoniene.
-
Oct 17, 2026, 09:05Addressing the Hidden Burden of Bleeding Disorders in Women – Hemophilia Society Mumbai Chapter
-
Oct 17, 2026, 08:49Maria Magnusson: Karolinska Experts Explore Gene Therapy in Sickle Cell Disease and Hemophilia
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026